Marco Meglio

Daniel Lowenstein, MD, professor of neurology and executive vice chancellor and provost at the University of California, San Francisco, discussed the ongoing trials and steps being taken to turn the gut microbiome into a realistic therapeutic option for patients with epilepsy.

The cross-company collaborative will be supported by 8 sponsors and will make no-charge genetic testing available for all children under 8 with unprovoked seizures.

Lara Jehi, MD, professor of neurology and co-director of Network Capacity for the Clinical and Translational Science Collaborative of Cleveland Clinic, has been appointed as the inaugural chief research information officer.

Daniel Lowenstein, MD, professor of neurology and executive vice chancellor and provost at the University of California, San Francisco spoke to the research on the gut microbiome and its parallels to epilepsy.

The trial will determine whether autologous hematopoietic stem cell transplantation is a more appropriate treatment option for patients with severe forms of relapsing MS compared to currently available biologic drugs.

The drug was associated with significant improvements in sleep onset, sleep efficiency, and wake-after-sleep onset for both doses compared with placebo.

The newly created 28-question assessment showed improved item targeting compared with the current standard Amyotrophic Lateral Sclerosis Functional Rating Scale.

Lasmiditan was efficacious across a number of doses in patients with migraine regardless of prior good or insufficient response to triptan administration.

The results pave the way for a potential phase 3 trial to examine the effects of nilotinib in patients with Parkinson disease.

A standardized treatment protocol in emergency departments lead to significant reductions in headache pain.

Wave Life Sciences has discontinued its suvodirsen clinical trials after investigators saw no change from baseline in either of the dose groups.

A new trial will aim to confirm the findings of a previous study that showed novel combinations of peripherally circulating proteins coupled with risk factors can provide a diagnostic tool with significant clinical unity.

Although the study did not meet primary and secondary endpoints in patients with PSP, Biogen still plans to continue to study the drug for mild cognitive impairment in Alzheimer disease.

Electroencephalography-functional magnetic resonance imaging can better identify the epileptogenic focus, resulting in a direct impact on patient management and surgery decision-making.

Patients were more affected by seizure cluster control and need for additional midazolam dosing than post-dose somnolence.

Data suggests that treatment with cannabidiol is associated with other benefits besides a decrease in seizure frequency.

Adjunctive cenobamate demonstrated a good tolerability and safety profile, as well as sustained efficacy, in patients with uncontrolled focal seizures.

Fenfluramine oral solution is currently being evaluated by the FDA for the treatment of seizures associated with Dravet syndrome.

Patients treated with intranasal midazolam who were on enzyme-inducing AEDs experienced numerically lower treatment-emergent adverse events.

The American Epilepsy Society recognized several members from its clinical and research communities for their outstanding contributions to the field of epilepsy.

An analysis of 2 different doses of intranasal diazepam showed consistent safety and tolerability results for repeat dosing

Although there are gaps in knowledge, investigators see potential in telemedicine for other neurologic disorders beyond stroke.

Results of the phase 3 ACHIEVE I trial showed a high percentage of patients were free from their most bothersome symptoms 2 hours post dose.

The director emeritus of the Cleveland Clinic Lou Ruvo Center for Brain Health discussed the significance of the HARMONY study findings and what they mean for the future treatment of dementia-related psychosis.

The drug was proven to be efficacious and generally well tolerated in adults with newly diagnosed epilepsy.

Patients who were administered levetiracetam, fosphenytoin, or valproate saw similar improvements in seizure reduction and responsiveness.

Top line results from the phase 3 trial of sovateltide in patients with acute cerebral ischemic stroke are expected by mid-2020.

No progressive or delayed complications of treatment were recorded after 3 years in patients with essential tremor who underwent focused ultrasound.

The private-public partnership aims to share patient data in hopes of uncovering new biomarkers related to Parkinson disease.

Fenfluramine is set for priority review by the FDA with a PDUFA date of March 25, 2020.